109 patents currently held
33 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next US patent term in the Cancer Research Technology Limited portfolio ends in Dec 2026, and more of its terms end in 2036 (14) than in any other year. from the record
Of the 33 now held by other companies, 6 name Windtree Therapeutics Inc. as their current owner, and 27 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
15
Ending by 2030
Dec 2026
Next term end
75
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends no later than Sep 2036 · Medium confidence
Also notable
Ends no later than Apr 2037 · Medium confidence
Also notable
Ends Jan 2031 · High confidence
Also notable
Ends Mar 2039 · High confidence
Also notable
Ends Mar 2038 · High confidence
Also notable
Ends no later than Apr 2037 · Medium confidence
Also notable
Ends Dec 2035 · High confidence
Also notable
Ends Jun 2039 · High confidence
Isoindolinone Inhibitors of the MDM2-P53 Interaction Having Anticancer Activity
US 10,544,132
Cited by 16 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2036. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Heterocyclic Compounds as Ret Kinase Inhibitors
US 10,954,241
Cited by 10 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2037. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Ortho-Condensed Pyridine and Pyrimidine Derivatives (E.G., Purines) as Protein Kinases Inhibitors
US 8,546,407
The most cited patent in this portfolio, cited by 28 later US patents, top 25% of utility patents granted in 2013 in our data. Protection runs to 2031.
ANTI-CD25 Antibody Agents
US 10,745,485
Cited by 21 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2039.
Isoindolinone Inhibitors of the MDM2-P53 Interaction and Process for Making Them
US 11,603,367
Cited by 5 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2038.
Heterocyclic Compounds as Ret Kinase Inhibitors
US 10,844,067
Cited by 11 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2037. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Parg Inhibitory Compounds
US 10,508,086
A family of 5 related applications built on the 2019 grant. Protection runs to 2035.
BCL6 Inhibitors
US 11,512,095
Granted 2022. Computed term ends 2039.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Dec 9 to 20, 2026 · next Dec 9
- 1 fee due Jan 11, 2027The maintenance fee for ANTI-CD25 for Tumour Specific Cell Depletion (US 11,697,688) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
- 5 fees due Mar 3 to 26, 2027 · next Mar 3
- 5 fees due Apr 1 to 30, 2027 · next Apr 1
- 3 fees due May 14 to 19, 2027 · next May 14
- 3 fees due Jun 10 to 26, 2027 · next Jun 10
- 5 fees due Jul 7 to 30, 2027 · next Jul 7
- 2 fees due Aug 9 to 13, 2027 · next Aug 9
- 2 fees due Sep 5, 2027
- 3 fees due Nov 5 to 19, 2027 · next Nov 5
Recent changes
- 2 of the patents on this record were granted since Aug 24, 2026
- 1 term has ended since Aug 24, 2026
- Sep 20 US 11,447,505 Pyrrolo[2,3-b]pyridine Compounds and Their Use in the Treatment of Cancer · lapsed on the fee record
What they patent
The largest of its 75 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Fused 1,4-Dihydrodioxin Derivatives as Inhibitors of Heat Shock Transcription Factor 1 | 4 in force | to Oct 2034 |
| Inhibitor Compounds | 4 in force | to Sep 2033 |
| Anti-CD19 antibodies with reduced immunogenicity | 4 in force | to Aug 2031 |
| 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | 3 in force | to Feb 2037 |
| Parg Inhibitory Compounds | 3 in force | to Dec 2035 |
| 5-[[4-[[MORPHOLIN-2-YL]METHYLAMINO]-5-(TRIFLUOROMETHYL)-2-Pyridyl]AMINO]PYRAZINE-2-Carbonitrile and Therapeutic Uses Thereof | 3 in force | to Jan 2034 |
| New Therapeutic Agents | 3 in force | to Oct 2029 |
| BCL6 Inhibitors | 2 in force | to Jun 2039 |
| Compounds Useful as RET Inhibitors | 2 in force | to Apr 2038 |
| Isoindolinone Inhibitors of the MDM2-P53 Interaction and Process for Making Them | 2 in force | to Mar 2038 |
| Pyrimidinone Derivatives as CDC7 Inhibitors | 2 in force | to Nov 2037 |
| Heterocyclic Compounds as Ret Kinase Inhibitors (2018) | 2 in force | to Nov 2037 |
| Immunomodulatory Antibodies | 2 in force | to Oct 2037 |
| Heterocyclic Compounds as Ret Kinase Inhibitors (2018) | 2 in force | to Apr 2037 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,957,195 | ANTI-CD19 Antibodies with Reduced Immunogenicity In force · High confidence | In force | High confidence | |
| US 8,258,175 | ISOINDOLIN-1-ONE Derivatives In force · High confidence | In force | High confidence | |
| US 11,208,496 | ANTI-CD19 Antibodies with Reduced Immunogenicity In force · High confidence | In force | High confidence | |
| US 9,919,023 | Anti-Androgen Peptides and Uses Thereof in Cancer Therapy In force · High confidence | In force | High confidence | |
| US 11,560,406 | Anti-Androgen Peptides and Uses Thereof in Cancer Therapy In force · High confidence | In force | High confidence | |
| US 10,072,092 | Methods of Use of ANTI-CD19 Antibodies with Reduced Immunogenicity In force · High confidence | In force | High confidence | |
| US 8,058,045 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE and PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE Compounds and Their Use In force · High confidence | In force | High confidence | |
| US 8,367,658 | PYRAZIN-2-YL-PYRIDIN-2-YL-AMINE and PYRAZIN-2-YL-PYRIMIDIN-4-YL-AMINE Compounds and Their Use In force · High confidence | In force | High confidence | |
| US 9,012,633 | [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use In force · High confidence | In force | High confidence | |
| US 8,796,293 | Purine and Deazapurine Derivatives as Pharmaceutical Compounds held by Astex Therapeutics Limited, The Institute of Cancer Research: Royal Cancer Hospital and Cancer Research Technology Limited In force · High confidence | In force | High confidence |
Also on record, not counted in the 109: 33 patents in force now held by others · 137 patents ended · 61 applications pending · 119 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.